ETERNAL
Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle
Objectives
ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only the API and residues/metabolites, but other chemicals and by-products of the production process. This type of approach is essential to take into consideration the types of green manufacturing approach under consideration by the pharmaceutical industry, as evidenced by the range and scope of case studies being undertaken within ETERNAL. Specific application of our risk and life cycle assessment approaches to the ETERNAL case studies is a key element of the proposed work and will provide industry and policymakers with key examples of how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction of green manufacturing processes.
Description
While emerging green manufacturing processes bode well for the environment, their impacts on industry need to be considered and addressed. The EU-funded project ETERNAL intends to contribute to the sustainable development of manufacturing, use and disposal of pharmaceuticals. It will promote a full life-cycle approach to support this sustainability, as well as assess the environmental risks of the production process. Project research involves a wide scope of case studies. Targeted application of ETERNAL’s risk and life-cycle assessment approaches to these studies aims to facilitate the work of industry and policymakers as green manufacturing starts to take centre stage.
Financing
